Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor
Authors:
Open Access
- 28 June 2016
- journal article
- research article
- Published by Wiley in Genes to Cells
- Vol. 21 (8) , 852-860
Abstract
Synovial sarcoma is a soft‐tissue sarcoma and a rare type of cancer. Unfortunately, effective chemotherapies for synovial sarcomas have not been established. In this report, we show that synovial sarcoma cell lines have reduced repair activity for DNA damage induced by ionizing radiation (IR) and a topoisomerase II inhibitor (etoposide). We also observed reduced recruitment of RAD51 homologue (S. cerevisiae; RAD51) at sites of double‐strand breaks (DSBs) in synovial sarcoma cell lines that had been exposed to IR. These findings showed that synovial sarcoma cell lines are defective in homologous recombination (HR) repair. Furthermore, we found that a poly‐(ADP‐ribose) polymerase (PARP) inhibitor (AZD2281; olaparib) effectively reduced the growth of synovial sarcoma cell lines in the presence of an alkylating agent (temozolomide). Our findings offer evidence that treatment combining a PARP inhibitor and an alkylating agent could have therapeutic benefits in the treatment of synovial sarcoma.Keywords
Funding Information
- Practical Research for Innovative Cancer Control (15ck0106089 h0002)
- Japan Agency for Medical Research and development, AMED
This publication has 32 references indexed in Scilit:
- Playing the End Game: DNA Double-Strand Break Repair Pathway ChoiceMolecular Cell, 2012
- Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT–SSX2Oncogene, 2011
- BLM–DNA2–RPA–MRN and EXO1–BLM–RPA–MRN constitute two DNA end resection machineries for human DNA break repairGenes & Development, 2011
- Susceptibility Pathways in Fanconi's Anemia and Breast CancerNew England Journal of Medicine, 2010
- DNA Damage, Aging, and CancerNew England Journal of Medicine, 2009
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid TumorsClinical Cancer Research, 2008
- Neuronal Differentiation of Synovial Sarcoma and Its Therapeutic ApplicationClinical Orthopaedics and Related Research, 2008
- The DNA Damage Response: Ten Years AfterMolecular Cell, 2007
- The SYT-SSX Fusion Protein Down-Regulates the Cell Proliferation Regulator COM1 in t(x;18) Synovial SarcomaMolecular and Cellular Biology, 2007
- DNA Lesion-specific Co-localization of the Mre11/Rad50/Nbs1 (MRN) Complex and Replication Protein A (RPA) to Repair FociJournal of Biological Chemistry, 2005